Esophageal Cancer Risk Increases with Hot Tea Consumption

Consuming hot tea may increase the risk of esophageal cancer among smokers who drink alcohol, according to a recent study published by the Annals of Internal Medicine.
Esophageal cancer rates are increasing worldwide and are linked to poor patient outcomes, especially in less-developed countries and among men. The authors noted that China has the highest esophageal cancer rate and Chinese men who drink tea are also more likely to smoke and drink alcohol.
Included in the study were 456,155 patients aged 30 to 79 years who were not diagnosed with cancer or who reduced their tea drinking, alcohol intake, or cigarette smoking at baseline. Patients were followed for 9.2 years.
The authors discovered a synergistic link between drinking hot tea with excessive alcohol intake or smoking with the risk of esophageal cancer, according to the study.
The risk of esophageal cancer was found to be 5 times higher among patients who drank hot tea, drank alcohol, and smoked compared with those who did not partake in any of those habits.
However, the researchers noted that hot tea consumption was not linked to an increased cancer risk among patients who abstained from alcohol and smoking, according to the study.
These findings suggest that patients who drink alcohol excessively or smoke may benefit from not drinking hot tea, according to the authors.
Another recent study found that Americans are unaware of behaviors that have been proven to cause cancer. Less than 4 in 10 participants realized alcohol consumption is linked to cancer, despite growing evidence that it can cause colorectal, breast, liver, and esophageal cancers.
Increasing education about the link between cancer and consumption of alcohol and hot beverages would likely reduce the burden of esophageal cancer, the authors concluded.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.
Top news of the week from Specialty Pharmacy Times.
The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.